Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurobiological Tech (NTII) -- Ignore unavailable to you. Want to Upgrade?

To: Dr. John M. de Castro who wrote (389)	11/19/1998 10:59:00 AM
From: BRAVEHEART	Read Replies (2) \| Respond to of 1494

Hi Gang, Why hasn't NTII sought orphan drug status for Memantine for Aid's related Dementia? It would provide potential cash through grants. Along with seven years protection for an indication where there are no existing treatments. Does anyone have any insight on this matter? Is the patient population too big to receive such status? Also is it not possible that Memantine would be used as a prevenative measure in many patients if the common stages of neuronal destruction is anticipated as a consequence of the disease state? Jeffrey